Clinical Research Directory
Browse clinical research sites, groups, and studies.
Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)
Sponsor: Gylden Pharma Ltd
Summary
The study aims to investigate the safety and immunogenicity of one dose vs two doses of a T-cell priming next-generation vaccine against Coronavirus disease.
Official title: A Phase I-II, Blinded, Randomized, Placebo-controlled Study of a T Cell Priming Next-generation Vaccine Against Coronavirus Disease in Healthy Adults
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
110
Start Date
2025-09-01
Completion Date
2026-12-01
Last Updated
2025-02-24
Healthy Volunteers
Yes
Conditions
Interventions
PepGNP-COVID19 (One vaccination)
One dose with 7.5 nmol total peptide/dose with 47.8ug gold base particle in 50 µl WFI
Water for injection (One vaccination)
Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose
PepGNP-COVID19 (Two vaccinations)
Two vaccinations with 7.5 nmol total peptide/dose with 47.8ug gold base particle in 50 µl WFI
Water for injection (Two vaccinations)
Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose
Locations (2)
Health Index Multispecialty Clinic, Barangay Toclong 2B
Imus, Cavite, Philippines
Tropical Disease Foundation
Makati City, National Capital Region, Philippines